Company intelligence / Profile preview

Leadingtac Biotech

Shanghai, Shanghai, Chinaen.leadingtac.com ↗

Ownership: Private
Employees: ~20
Development stage: Phase 2

Overview

LT‑002 demonstrated good safety/tolerability in over a hundred healthy volunteers with favorable pharmacokinetics and strong IRAK4 protein degradation in human PBMCs and skin. Marked inhibition of pro-inflammatory cytokines was observed. The program has regulatory clearance to proceed to clinical trials both in China and the US.

Therapeutic areas: OncologyImmunologyHematology
Modalities: Small moleculesProteolysis-targeting chimeras (PROTACs)Molecular glues
Industry: Biotech

Drug pipeline

2 assets

OD-07656

Phase 2

Indications: Ulcerative colitis

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Leadingtac Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Leadingtac Biotech.

Explore the full profile